

elf atochem

ELF ATOCHEM NORTH AMERICA, INC.
900 First Avenue, P.O. Box 1536
King of Prussia, PA 19406-0018

Tel: 215-337-6500

Contains No CBI

September 29, 1992

A

CERTIFIED MAIL

RETURN RECEIPT REQUESTED

Document Processing Center (TS-790)
Office of Toxic Substances
U.S. Environmental Protection Agency
401 M St., S.W.
Washington, D.C. 20460

Attn: Section 8(e) Coordinator (CAP Agreement)

RE: Report Submitted Pursuant to the TSCA Section 8(e)
Compliance Audit Program

CAP Identification Number: 8ECAP-0026

Dear Sir/Madam:

Pursuant to the Toxic Substances Control Act (TSCA) Section 8(e) Compliance Audit Program and the Agreement for TSCA Section 8(e) Compliance Audit Program (CAP Agreement) executed by Elf Atochem North America Inc. (Atochem) and the Environmental Protection Agency (EPA), Atochem is submitting the enclosed one-hour vapor toxicity in mice study to the EPA. This study does not involve effects in humans.

Nothing in this letter or the enclosed study is considered confidential business information of Atochem.

The enclosed study provides information on the chemical isopropyl mercaptan. Its exact chemical name is 2-propanethiol and its CAS number is 75-33-2.

The title of the enclosed study is One-Hour Vapor Toxicity in Mice. The following is a summary of the adverse effects observed in this study.

Groups of five male mice were exposed to vapors of isopropyl mercaptan for 1-hour at concentrations of 40, 55, 80, 110 and 160 mg/l. All concentrations were expressed as nominal concentrations. The LC_{50} was calculated to be 130 mg/l. Three of four surviving mice at 110 mg/l exhibited severe hypertonic dysmetria (resembles Parkinson's disease).

8EHQ-92-12610

88920010793

INIT

SEP 29 1992 11:58

3/1/95

TSCA CAP
Isopropyl Mercaptan
September 29, 1992
Page Two

To our knowledge, Atochem has not previously submitted any TSCA Section 8(e) notices or premanufacture notifications on the subject chemical.

Further questions regarding this submission may be directed to me at 215 337-6892.

Sincerely,

A handwritten signature in cursive script, appearing to read "C.H. Farr".

C.H. Farr, PhD, DABT
Manager, Product Safety
and Toxicology

Enclosures

7/2 MN 18-35 (TRC vault)
R. LATVEN
Director

PHARMACOLOGY RESEARCH,
INC.

TR 77-78
BOX 70, 21 MAIN STREET
DARBY, PA. 19023
(215) 586-0707

On Microfilm
Microfilm

11 MAY 1977

MR. GEORGE I. ABBOTT
CORPORATE INDUSTRIAL HYGIENIST
PENNWALT CORPORATION
900 FIRST AVENUE
KING OF PRUSSIA, PA. 19406

DEAR MR. ABBOTT:

TR 77-78
ENCLOSED ARE REPORTS IN REFERENCE TO SPOTLEAK #1099 AND ^{TR 77-101} 2509-
ISOPROPYL MERCAPTAN. BOTH PRODUCTS HAVE A RELATIVELY LOW ORDER NO; 18-
OF TOXICITY. 85

WE APOLOGIZE FOR HAVING TAKEN SO LONG TO COMPLETE THESE
STUDIES AND WE APPRECIATE YOUR PATIENCE IN THIS REGARD. THE
REMAINING THREE MERCAPTANS WILL BE REPORTED VERY SOON.

SINCERELY YOURS,

A. R. Latven

A. R. LATVEN
PHARMACOLOGY RESEARCH, INC.

ENC: 2 REPORTS + 3 COPIES EACH
STATEMENT + 3 CC
2 REQUEST FORMS

CAS: 75-33-2



FORM 1025

T.R.C.

SUBJECT 905-IPM-65 (2316) - TOXICITY EVALUATION
DATE May 15, 1970
TO Mr. I. W. Harvey
FROM George I. Abbott
IN REPLY TO
COPIES TO T.R.C. (Original)

Attached for your information and use is the toxicity evaluation
for 905-IPM-65 (2316).

905-IPM-65 (2316)

NAME: iso-Propyl Mercaptan

FORMULA:

COLOR & PHYS. STATE: A malodorous, clear, colorless liquid.

ODOR: Malodorous.

EVALUATION REQUEST BY: Mr. I. W. Harvey

EVALUATION COST: \$120.00.

GIA:jwb
Att.

George I. Abbott

TOXICITY REPORT
FOR PENNWALT CORPORATIONRE: SAMPLE 905-IPM-65 (2316) (ISOPROPYL MERCAPTAN)

A MALODOROUS, CLEAR, COLORLESS LIQUID; AMBIENT SP GR = 0.814.

SUMMARY. ONE-HOUR VAPOR TOXICITY IN MICE: $LC_{50} = 130$ MG/LITER.ONE-HOUR VAPOR TOXICITY IN MICE.

METHOD. GROUPS OF FIVE ♂ CF_1 MICE, $24 \pm$ G BW, WERE EXPOSED TO PREPARED VAPOR CONCENTRATIONS IN STATIC 20-LITER CHAMBERS FOR SIXTY MINUTES. THE ANIMALS WERE OBSERVED CONTINUOUSLY FOR SEVERAL HOURS AND DAILY FOR SEVEN DAYS.

RESULTS.

| ML SAMPLE* IN CHAMBER | VAPOR CONC MG/LITER | NO. MICE DEAD/TOTAL | MORTALITY | TIME FOR DEATH MINUTES |
|--------------------------|------------------------|------------------------|-----------|---------------------------|
| 0.98 | 40 | 0 / 5 | 0 % | - - - - - |
| 1.35 | 55 | 0 / 5 | 0 % | - - - - - |
| 1.96 | 80 | 0 / 5 | 0 % | - - - - - |
| 2.70 | 110 | 1 / 5 | 20 % | - - - - 85 |
| 3.93 | 160 | 5 / 5 | 100 % | 12,30,35,35,45 |

*As a LIQUID.

 $LC_{50} = 130$ MG/LITER.

SYMPTOMATOLOGY: HYPOTONICITY, ATAXIA, LOSS OF RIGHTING REFLEX (ANESTHESIA). THREE SURVIVORS OF 110 MG/L SHOWED SIGNS OF CNS DAMAGE: SEVERE HYPERTONIC DYSMETRIA (RESEMBLES PARKINSON'S DISEASE).

PHARMACOLOGY RESEARCH, INC.

By



A. R. LATVEN 5/11/70

PROTOCOL REFS: PR#70.4815; ARL XXV,10.



UNITED STATES ENVIRONMENTAL PROTECTION AGENCY
WASHINGTON, D.C. 20460

C. H. Farr, PhD, DABT
Manager, Product Safety and Toxicology
Atochem North America, Inc.
900 First Avenue
P.O. Box 1536
King of Prussia, Pennsylvania 19406-0018

OFFICE OF
PREVENTION, PESTICIDES AND
TOXIC SUBSTANCES

APR 24 1995

EPA acknowledges the receipt of information submitted by your organization under Section 8(e) of the Toxic Substances Control Act (TSCA). For your reference, copies of the first page(s) of your submission(s) are enclosed and display the TSCA §8(e) Document Control Number (e.g., 8EHQ-00-0000) assigned by EPA to your submission(s). Please cite the assigned 8(e) number when submitting follow-up or supplemental information and refer to the reverse side of this page for "EPA Information Requests".

All TSCA 8(e) submissions are placed in the public files unless confidentiality is claimed according to the procedures outlined in Part X of EPA's TSCA §8(e) policy statement (43 FR 11110, March 16, 1978). Confidential submissions received pursuant to the TSCA §8(e) Compliance Audit Program (CAP) should already contain information supporting confidentiality claims. This information is required and should be submitted if not done so previously. To substantiate claims, submit responses to the questions in the enclosure "Support Information for Confidentiality Claims". This same enclosure is used to support confidentiality claims for non-CAP submissions.

Please address any further correspondence with the Agency related to this TSCA 8(e) submission to:

Document Processing Center (7407)
Attn: TSCA Section 8(e) Coordinator
Office of Pollution Prevention and Toxics
U.S. Environmental Protection Agency
Washington, D.C. 20460-0001

EPA looks forward to continued cooperation with your organization in its ongoing efforts to evaluate and manage potential risks posed by chemicals to health and the environment.

Sincerely,

Terry R. O'Bryan
Terry R. O'Bryan
Risk Analysis Branch

Enclosure

12610A



Recycled/Recyclable
Printed with Soy/Canola Ink on paper that
contains at least 50% recycled fiber

Triage of 8(e) Submissions

Date sent to triage: 12/14/95

NON-CAP

CAP

Submission number: 12610A

TSCA Inventory:

Y

N

D

Study type (circle appropriate):

Group 1 - Dick Clements (1 copy total)

ECO

AQUATO

Group 2 - Ernie Falke (1 copy total)

ATOX

SBTOX

SEN

w/NEUR

Group 3 - Elizabeth Margosches (1 copy each)

STOX

CTOX

EPI

RTOX

GTOX

STOX/ONCO

CTOX/ONCO

IMMUNO

CYTO

NEUR

Other (FATE, EXPO, MET, etc.):

Notes:

THIS IS THE ORIGINAL 8(e) SUBMISSION; PLEASE REFILE AFTER TRIAGE DATABASE ENTRY

For Contractor Use Only

entire document: 0 1 2 pages 42

pages 42, TAB

Notes:

Contractor reviewer: FOR

Date: 4/18/95

CECATS TRIAGE TRACKING DBASE ENTRY FORM

CECATS DATA: Submission # BEHQ-1092-12610 SEQ. A
TYPE: INT. SUPP FLWP
SUBMITTER NAME: Elf Atochem North America, Inc.

INFORMATION REQUESTED: FLWP DATE: _____
0501 NO INFO REQUESTED
0502 INFO REQUESTED (TECH)
0503 INFO REQUESTED (VOL ACTIONS)
0504 INFO REQUESTED (REPORTING RATIONALE)
DISPOSITION:
0505 REFER TO CHEMICAL SCREENING
0506 CAP NOTICE

SUB. DATE: 09/29/92 OTS DATE: 10/08/92 CSRAD DATE: 03/01/95
CHEMICAL NAME: _____
CASE: 75-33-2

OPTIONARY ACTIONS:
0401 NO ACTION REQUIRED
0402 STUDY'S PLANNING (DURING HWAY)
0403 NOTIFICATION (WORKER IN PROGRESS)
0404 LABELS/ASSETS (TIANCHIS)
0405 PROCESS/ANALYSIS (TIANCHIS)
0406 APPAUSE DISCONTINUED
0407 PRODUCTION DISCONTINUED
0408 CONFIDENTIAL

| INFORMATION TYPE: | P F C | INFORMATION TYPE: | P F C |
|-------------------------------|----------|--------------------------------|----------|
| 0201 ONCO (HUMAN) | 01 02 04 | 0216 EPICLIN | 01 02 04 |
| 0202 ONCO (ANIMAL) | 01 02 04 | 0217 HUMAN EXPOS (PROD CONTAM) | 01 02 04 |
| 0203 CELL TRANS (IN VITRO) | 01 02 04 | 0218 HUMAN EXPOS (ACCIDENTAL) | 01 02 04 |
| 0204 MUTA (IN VITRO) | 01 02 04 | 0219 HUMAN EXPOS (MONITORING) | 01 02 04 |
| 0205 MUTA (IN VIVO) | 01 02 04 | 0220 BIOAQUA TOX | 01 02 04 |
| 0206 REPRO/TERATO (HUMAN) | 01 02 04 | 0221 ENV. OCCURRENCE/FATE | 01 02 04 |
| 0207 REPRO/TERATO (ANIMAL) | 01 02 04 | 0222 EMER INCI OF ENV CONTAM | 01 02 04 |
| 0208 NEURO (HUMAN) | 01 02 04 | 0223 RESPONSE REQUEST DELAY | 01 02 04 |
| 0209 NEURO (ANIMAL) | 01 02 04 | 0224 PRODNOM/ACHEM ID | 01 02 04 |
| 0210 ACUTE TOX (HUMAN) | 01 02 04 | 0225 REPORTING RATIONALE | 01 02 04 |
| 0211 CHR. TOX (HUMAN) | 01 02 04 | 0226 CONFIDENTIAL | 01 02 04 |
| 0212 ACUTE TOX (ANIMAL) | 01 02 04 | 0227 ALLERG (HUMAN) | 01 02 04 |
| 0213 SUB ACUTE TOX (ANIMAL) | 01 02 04 | 0228 ALLERG (ANIMAL) | 01 02 04 |
| 0214 SUB CHRONIC TOX (ANIMAL) | 01 02 04 | 0229 METAB/PHARMACO (ANIMAL) | 01 02 04 |
| 0215 CHRONIC TOX (ANIMAL) | 01 02 04 | 0230 METAB/PHARMACO (HUMAN) | 01 02 04 |
| | | 0231 MEDS | 01 02 04 |
| | | 0232 OTHER | 01 02 04 |
| | | 0233 | 01 02 04 |
| | | 0234 | 01 02 04 |
| | | 0235 | 01 02 04 |
| | | 0236 | 01 02 04 |
| | | 0237 | 01 02 04 |
| | | 0238 | 01 02 04 |
| | | 0239 | 01 02 04 |
| | | 0240 | 01 02 04 |
| | | 0241 | 01 02 04 |
| | | 0242 | 01 02 04 |
| | | 0243 | 01 02 04 |
| | | 0244 | 01 02 04 |
| | | 0245 | 01 02 04 |
| | | 0246 | 01 02 04 |
| | | 0247 | 01 02 04 |
| | | 0248 | 01 02 04 |
| | | 0249 | 01 02 04 |
| | | 0250 | 01 02 04 |
| | | 0251 | 01 02 04 |
| | | 0252 | 01 02 04 |
| | | 0253 | 01 02 04 |
| | | 0254 | 01 02 04 |
| | | 0255 | 01 02 04 |
| | | 0256 | 01 02 04 |
| | | 0257 | 01 02 04 |
| | | 0258 | 01 02 04 |
| | | 0259 | 01 02 04 |
| | | 0260 | 01 02 04 |
| | | 0261 | 01 02 04 |
| | | 0262 | 01 02 04 |
| | | 0263 | 01 02 04 |
| | | 0264 | 01 02 04 |
| | | 0265 | 01 02 04 |
| | | 0266 | 01 02 04 |
| | | 0267 | 01 02 04 |
| | | 0268 | 01 02 04 |
| | | 0269 | 01 02 04 |
| | | 0270 | 01 02 04 |
| | | 0271 | 01 02 04 |
| | | 0272 | 01 02 04 |
| | | 0273 | 01 02 04 |
| | | 0274 | 01 02 04 |
| | | 0275 | 01 02 04 |
| | | 0276 | 01 02 04 |
| | | 0277 | 01 02 04 |
| | | 0278 | 01 02 04 |
| | | 0279 | 01 02 04 |
| | | 0280 | 01 02 04 |
| | | 0281 | 01 02 04 |
| | | 0282 | 01 02 04 |
| | | 0283 | 01 02 04 |
| | | 0284 | 01 02 04 |
| | | 0285 | 01 02 04 |
| | | 0286 | 01 02 04 |
| | | 0287 | 01 02 04 |
| | | 0288 | 01 02 04 |
| | | 0289 | 01 02 04 |
| | | 0290 | 01 02 04 |
| | | 0291 | 01 02 04 |
| | | 0292 | 01 02 04 |
| | | 0293 | 01 02 04 |
| | | 0294 | 01 02 04 |
| | | 0295 | 01 02 04 |
| | | 0296 | 01 02 04 |
| | | 0297 | 01 02 04 |
| | | 0298 | 01 02 04 |
| | | 0299 | 01 02 04 |
| | | 0300 | 01 02 04 |

TRIAGE DATE: 09/29/92 NON-DB INVENTORY: YES
CAS SR: NO
YES (DROP/REFER) NO
NO (CONTINUE) NO
REFR: NO
SPECIES: MUS
TOXICOLOGICAL CONCERN: LOW
PRODUCTION: Acute Inhalation Toxicity

12610A

Acute Inhalation Toxicity - Low

Acute inhalation toxicity is low based on a calculated 1 hour LC_{50} of 130 mg/L in mice. Mortality and corresponding doses (mg/L) were 0/5 (40, 55, 80), 1/5 (110), and 5/5 (160). Clinical signs included hypotonicity, ataxia, and loss of righting reflex (doses not reported). Survivors of 110 mg/L exposure were noted to have CNS damage.